Chronic myelogenous leukemia: mechanisms underlying disease progression.
about
Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signalingMicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemiaEffect of cellular quiescence on the success of targeted CML therapyCombination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemiaOptimizing combination therapies with existing and future CML drugsIcaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalingsEffectiveness of imatinib mesylate over etoposide in the treatment of sensitive and resistant chronic myeloid leukaemia cells in vitroRNA quantification using gold nanoprobes - application to cancer diagnosticsBCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells.Identification of genes potentially involved in disease transformation of CML.Gene expression changes associated with progression and response in chronic myeloid leukemia.Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid LeukemiaExpression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia.Advances in targeted therapy for chronic myeloid leukemia.SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl.Acute promyelocytic leukemia: where does it stem from?A closer look at specific therapeutic strategies in leukemia.Nanotechnology applications in hematological malignancies (Review).Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.Comprehensive Analysis of MILE Gene Expression Data Set Advances Discovery of Leukaemia Type and Subtype Biomarkers.New Genetic Variation in BCR gene of Major B3a2 Breakpoint BCR-ABL Fusion Gene in Patients with Chronic Myelogenous Leukemia in Yogyakarta, IndonesiaTargeted therapy in chronic myeloid leukemia.Signaling networks associated with BCR-ABL-dependent transformation.MiRNA182 regulates percentage of myeloid and erythroid cells in chronic myeloid leukemia.Telomere dysfunction and its role in haematological cancer.Functional endogenous LINE-1 retrotransposons are expressed and mobilized in rat chloroleukemia cells.Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients.Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation.Viral/Nonviral Chimeric Nanoparticles To Synergistically Suppress Leukemia Proliferation via Simultaneous Gene Transduction and Silencing.Aberrant methylation in promoter-associated CpG islands of multiple genes in chronic myelogenous leukemia blast crisisErythroid progenitor renewal versus differentiation: genetic evidence for cell autonomous, essential functions of EpoR, Stat5 and the GR.Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells.Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.Kinetics of hematopoiesis in bone marrow cultures from patients with chronic myeloid leukemia: effect of recombinant cytokines in dexter-type long-term cultures.A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.Association of XRCC1 gene polymorphisms with chronic myeloid leukemia in the population of Andhra Pradesh, India.Karyotype abnormalities and their clinical significance in a group of chronic myeloid leukemia patients treated with hematopoietic stem cell transplantation.hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia.Dysregulated expression of SKP2 and its role in hematological malignancies.Targeting cancer stem cells and signaling pathways by resveratrol and pterostilbene.
P2860
Q24685070-5E7093EA-65BD-46FA-86D8-BA1B275CE6FDQ26766288-B887965A-52E8-4268-B13D-1506900EE5A9Q28469312-723735A9-DAB6-4698-A496-9343975298CDQ28474737-8594705C-FE2C-462D-8BBA-80B999B3ACE1Q28475255-385AFB08-98A4-46FD-9831-49458033EEACQ28741022-49FDB11E-C0AD-48BC-B630-9632A765FFF1Q33744180-59161C68-1E94-48C6-BDBA-096C9EAE4B08Q33748792-176358CC-107D-40B1-9665-67BF43B70222Q33796384-45F33CB5-B6A8-407A-A2E9-824FB763BD48Q34409580-E9FD0B65-F98A-49EC-91A4-D984E2AA294CQ34479561-D9D3EA04-6FFC-4FF9-ABA4-EC2F6A54958FQ34521001-E2D6D408-5A2E-4910-B2F2-4FC7F89E3DA3Q34532048-257CC93A-9C8D-4F92-9072-69CE830C6746Q35160190-A2B72450-2AF7-40DA-846D-2DB50FE82299Q35615838-EBFCBC62-FF8E-4827-9E57-B33370B9BC15Q35635316-1902DD6D-E3C1-4FD8-BF81-7FD119935BC3Q35821017-BCC250FD-353B-4470-920F-DCBA921A32A6Q35934466-CFE1C68A-DA37-4467-9557-D567BEA251F3Q36261941-7C4D3AE2-5A5A-421C-ABD7-2A11F69B1B61Q36311655-57CAA23C-2183-4473-8BB5-D43ED9CE3898Q36404921-77F81912-A60B-40FA-B74E-3D1D141690E0Q37038914-7E8EA66B-FC83-4399-BF63-1A0FC166F221Q37428655-F73FD9B7-A068-4A9F-8373-E551CD1E38F3Q37744933-5E20A520-9BBC-4932-880F-BCFDA12BA4EEQ37974664-15DDF197-884A-4E99-BEA5-5517719450DEQ40036708-93567EB7-EAE6-4841-8CE4-594C69B76F0BQ40321847-62DF4A91-D54C-47A1-BEFE-60523D4A173DQ40352522-DD208386-7225-4941-A850-0AC247519346Q41723749-4FD40445-5885-4FFC-A855-F62DFFFEDA2DQ41969916-7227CBE2-4FF5-43F3-B29A-DF2F7AD86101Q42041751-A2F217FD-12BD-429D-BA33-4A8E76E9EA97Q42380473-53BCAA6A-A726-467A-BB7C-66A8E1BA669DQ43078241-93359DA0-62ED-4241-ABEA-FF34ADA845ADQ44440140-AEEFFE5F-40D1-45BA-B416-D37F9A3BE75FQ44645852-1CCC8538-E1B9-4185-B22F-E91B0A0FA9FBQ44935412-27F0707D-6FFE-444E-8E4E-8BB76C38F571Q44981903-25132121-C560-41D4-BE98-8F2B87063BD7Q46960831-B9720AAE-E8C0-4F37-B50A-5DEA20F66962Q47967824-022630AE-166A-4781-80F7-A17796D870BFQ48179398-2DF2EF24-881F-4D2D-89F0-1D5A58FFE599
P2860
Chronic myelogenous leukemia: mechanisms underlying disease progression.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Chronic myelogenous leukemia: mechanisms underlying disease progression.
@ast
Chronic myelogenous leukemia: mechanisms underlying disease progression.
@en
Chronic myelogenous leukemia: mechanisms underlying disease progression.
@nl
type
label
Chronic myelogenous leukemia: mechanisms underlying disease progression.
@ast
Chronic myelogenous leukemia: mechanisms underlying disease progression.
@en
Chronic myelogenous leukemia: mechanisms underlying disease progression.
@nl
prefLabel
Chronic myelogenous leukemia: mechanisms underlying disease progression.
@ast
Chronic myelogenous leukemia: mechanisms underlying disease progression.
@en
Chronic myelogenous leukemia: mechanisms underlying disease progression.
@nl
P356
P1433
P1476
Chronic myelogenous leukemia: mechanisms underlying disease progression
@en
P2093
Jahagirdar BN
P2888
P304
P356
10.1038/SJ.LEU.2402577
P577
2002-08-01T00:00:00Z
P5875
P6179
1030621906